// App-Quantinova.ai

: Pharmacokinetics (PK) of Subcutaneous Daratumumab in Patients with Relapsed or Refractory (RR) Multiple Myeloma (MM): Primary Clinical Pharmacology Analysis of the Open-Label, Multicenter, Phase 1b Study (PAVO)

Researchers

Presenter

  • Pamela L Clemens

Principal Investigators

  • Melody Luo

  • Ajai Chari

  • Saad Z. Usmani

  • Maria-Victoria Mateos

  • Niels WCJ van de Donk

  • Jonathan L Kaufman

  • Philippe Moreau

  • Albert Oriol

  • Torben Plesner

  • Lotfi Benboubker

  • Jesus F San-Miguel

  • X. Yu-Nien Sun

  • Andrew Farnsworth

  • Tara Masterson

  • Peter Hellemans

  • Ming Qi

  • Hareth Nahi

Medical Centers

  • Janssen Research and Development, LLC, Spring House, PA

  • Tisch Cancer Center, Mount Sinai School of Medicine, New York, NY

  • Levine Cancer Institute, Atrium Health, Charlotte, NC

  • University Hospital of Salamanca, Salamanca, Spain

  • Department of Medical Oncology, VU University Medical Center, Amsterdam, Netherlands

  • Winship Cancer Institute of Emory University, Atlanta, GA

  • University Hospital Nantes, Nantes, France

  • ICO Institut Catala d'Oncologia, Barcelona, Spain

  • Vejle Hospital and University of Southern Denmark, Vejle, Denmark

  • Service dHematologie et Therapie Cellulaire, Hopital Bretonneau, Centre Hospitalier Regional Universitaire (CHRU), Tours, France

  • Clinica Universidad de Navarra-CIMA, IDISNA, CIBERONC, Pamplona, Spain

  • Janssen Research & Development, High Wycombe, United Kingdom

  • Janssen Research & Development, Beerse, Belgium

  • Karolinska Institute and the Department of Medicine, Division of Hematology, Karolinska University Hospital at Huddinge, Stockholm, Sweden

Locations

  • United States

  • Spain

  • Netherlands

  • France

  • Denmark

  • United Kingdom

  • Belgium

  • Sweden

Companies

  • JB Medical Ltd.

  • Janssen Global Servi

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Multiple Myeloma

Biomarkers

  • N/A

Drug/Treatment

  • daratumumab Intravenous

  • rHuPH20

  • Sparsentan

Outcome

  • N/A

Study Design

  • Pharmacokinetics

  • Fixed Dose

  • Open Label

  • Multicenteric

Phase

  • I

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved